COOPER COMPANIES, INC. News
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
see moreCOOPER COMPANIES, INC. Market News
27d
CooperCompanies: Board Shakeup Spurs COO Rally Now
- CooperCompanies (COO) saw a governance change and launched a formal strategic review the past week, accompanied by strong Q4 results, an expanded buyback program and bullish 2026 guidance—moves that pushed shares higher and prompted analyst target upgrades. This article breaks down the concrete developments, financials, and investor implications for the vision-care and women’s-health business units.
16 Feb at 04:18
COO Upside: March 5 Earnings & Board Shakeup Ahead
CooperCompanies (COO) faces a pivotal week as it reports Q1 on March 5. Board leadership changes, a formal strategic review and activist cooperation have set clear near-term catalysts.
09 Feb at 04:18
CooperCompanies COO: Board Shakeup Fuels Value Up
CooperCompanies (COO) has moved decisively on governance and capital allocation: a board refresh linked to activist Browning West, fiscal 2025 results showing modest organic growth, a $1B bump to buyback capacity, and a strategic review that could reshape CooperVision and CooperSurgical. These concrete actions — plus FY2026 guidance and cost-savings targets — create a clearer near-term playbook for investors.